Focus: Lipids and the endothelium

Slides:



Advertisements
Similar presentations
Atherosclerosis Mike Clark, M.D.. Terms Arteriosclerosis – hardening of the arteries Atherosclerosis – a form of arteriosclerosis Venosclerosis Arteriolosclerosis.
Advertisements

Stents Are Not Enough: Statins Keith Channon Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford.
PBL CV 2 Pathophysiology of coronary artery disease.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Journal Reading Myocardial infarction in young people Cardiol J 2009; 16, 4: 307–311 Cardiol J 2008; 15: 21–25 Presented by R 王郁菁 at ER conference.
Ischemic Heart Disease.  Coronary artery disease CAD is a general manifestation that dose not discriminate bet the various phases that the individual.
Aging of the Cardiovascular System (continued)
PATHOLOGY OF VASCULAR OCCLUSION, ATHEROSCLEROSIS, HYPERTENSION AND LYMPHEDEMA.
Ischemic Heart Diseases IHD
Atherosclerosis  hardening of the arteries due to the deposition of atheromas  heart disease is the leading cause of death  caused by the deposition.
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Global impact of ischemic heart disease World Heart Federation, 2011.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Antiplatelet Drugs - Principles Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.
Coronary Artery Disease Presented by: Marissa V. Dacumos Batch 17
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
Silent Ischemia STABLE CAD
ACE INHIBITION TRIALS IN CAD SECONDARY PREVENTION TREATMENT AFTER AMI EFFICACY BEFORE   EUROPA   HOPE   PEACE   QUIET   CONSENSUS 2   GISSI.
Atherosclerosis CVS 1 Hisham Al Khalidi. Atherosclerosis.wmv.
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.
Review of an article Not all Angiotension-Converting Enzyme (ACE) inhibitors are Equal: Focus on Ramipril and Perindopril DiNicolantonio J, Lavie C, O’Keefe.
atherosclerosis Jon Yap John A. Burns School of Medicine
HYPERLIPIDEMIA Applied Therapeutics Dr. Riyadh Mustafa Al-Salih.
Dr.Hesham Rashid, MD PATHOGENIC MECHANISMS OF ATHEROSCLEROSIS
Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.
4S: Scandinavian Simvastatin Survival Study
Clinical Trial Results. org METEOR Trial Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. John R.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pharmacologic plaque passivation for the reduction.
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Is atherosclerosis a metabolic disease?
The American College of Cardiology Presented by Dr. Adnan Kastrati
Association between Hypomagnesaemia and Hyperuricemia Accompany More Severe Forms of Atherosclerosis and Inflammatory Syndrome in Patients with Cardiovascular.
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
HOPE: Heart Outcomes Prevention Evaluation study
The American Heart Association Presented by Dr. Steven E. Nissen
Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations Cardiology 2015;132: DOI: / Fig. 1. Semilogarithmic.
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
FATS- Familial Atherosclerosis Treatment Study
The angiotensin converting enzyme (ACE) inhibitors, developed initially for blood pressure control, have become an essential part of the treatment of.
Section II: A primer on the endothelium
The following slides highlight a report on a presentation at the Canadian Cardiovascular Congress held in Toronto, Ontario from October 24 to 29, 2003.
Section 3: Role of lipids in endothelial function
Section IV: Dyslipidemia: Impact on the endothelium and CDS
The progression from CV risk factors to endothelial injury and clinical events Content Points: Well-recognized cardiovascular risk factors (hypertension,
Section I: RAS manipulation
Case 1: A 73-year-old white female with carotid disease
Type 2 diabetes: Overlap of clinical conditions
Section 7: Aggressive vs moderate approach to lipid lowering
Coronary Artery Disease and Acute Coronary Syndrome
Hyperlipidemia: A well-documented modifiable risk factor for stroke
Program Outline Content Points:
Section 9: Continuum of care: Summary and timeline
Section 4: Plaque dynamics and stenosis
Diabetes and atherosclerosis
LRC-CPPT and MRFIT Content Points:
Section IV: The interaction of the RAS and lipids
ARISE Trial Aggressive Reduction of Inflammation Stops Events
Correlation between endothelial function and hypertension
Endothelial function: Changing the pattern of treating CV disease
The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
Case 1: A 78-year-old white female with hypertension and hyperlipidemia Discussion Points: In that this patient has documented atherosclerotic vascular.
Endothelial regulation: Understanding RAS
Section 6: Update on lipid treatment guidelines
Cardiovascular Epidemiology and Epidemiological Modelling
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

Focus: Lipids and the endothelium Content Points: One of the newest and most exciting areas of cardiology research continues to focus on the earliest manifestations of coronary artery disease...endothelial dysfunction. Through its role as a regulator of vascular tone and structure, the endothelium is considerably influenced by cardiovascular risk factors, not the least of which is lipids.

Content outline Content Points: This slide program will review in detail the following points:   - Role of lipids in endothelial health.   - The links between coronary heart disease, cholesterol, and diabetes.   - The benefits of lipid lowering...a review of recent clinical trials.   - Guidelines for cholesterol lowering in clinical practice.   - Therapeutic implications. At the end of this program, three case histories are suggested. They were selected based on patient profiles commonly seen in clinical practice:   - A 73-year-old white female with carotid disease.   - A 48-year-old white male with angina.   - A 38-year-old white male with a family history of coronary artery disease. The purpose of including these cases is to enable speakers to turn the science of medicine into practical clinical medicine. Cases are described, followed by suggestions for opening up the discussion on how to approach those patients to reduce cardiovascular risk.

Endothelial health: A balancing act Content Points: Normal endothelial function is dependent on achieving a balance between nitric oxide activity and angiotensin II, and on normal oxidative metabolism in the arterial wall. At risk of oversimplification, it is helpful to examine some of the basic scientific background which provides the foundation for how lipids can disrupt normal oxidative metabolism. Dr. Victor Dzau’s group from Stanford (and more recently from Harvard Medical School) have hypothesized that medial smooth muscle cells and plaque lipid-laden macrophages express ACE. ACE expression in macrophages is induced by oxidatively modified LDL-C. Their hypothesis is that ACE is involved in modulation of plaque inflammation, and thus becomes a very important oxidant.1

Oxidative stress Content Points: The key point is that endothelial dysfunction promotes an imbalance among vasoactive substances. The vasoconstrictive substances (angiotensin II and tissue ACE) are increased, while the vasorelaxant or growth-inhibiting substances (Nitric Oxide) are decreased.2 The result is a condition of oxidative stress.

Oxidative stress hypothesis: A common pathogenic feature of CV risk factors Content Points: Risk factors that increase oxidative stress are the same as those for coronary artery disease, and include hypertension, diabetes, increased LDL-C, smoking, hyperhomocysteinemia and estrogen withdrawal. In the context of this lecture guide, LDL-C can be a critical risk factor. Endothelial dysfunction occurs in hypercholesterolemic patients, whether or not other coronary risk factors are present, and precedes the onset of coronary atherosclerosis.3,4

Effects of oxidative stress Content Points: Among the effects of oxidative stress, is the altered regulation of vascular tone. In addition, oxidative stress promotes a proinflammatory state, and imposes injury resulting in endothelial cell death.5,6,7

When LDL-C is oxidized... Content Points: These are some of the effects oxidized LDL-C can have on the vessel wall. There is increased production of oxygen free radicals and increased expression of endothelial-derived adhesion molecules. There is also increased migration of monocytes with enhanced entry into subendothelial space. A prothrombotic state occurs due to increased PAI-1 and decreased levels of tissue-plasminogin activator. There is also increased platelet aggregation due to decreases in nitric oxide (NO) and PGI2.5,6,7

Oxidized LDL-C: A common initiating factor for cardiac events Content Points: Effects of oxidized LDL-C seem to result in a destabilized vessel wall from an increasingly fragile plaque prone to rupture, decrease in flow-mediated dilatation, abnormal constriction, and a procoagulant vascular surface. These effects can lead to transient ischemia, unstable syndromes, myocardial infarction, and cardiac death.

Effects of cholesterol lowering on myocardial ischemia Content Points: Evidence for beneficial effects of lipid lowering on myocardial ischemia has been provided from groups working at the Brigham and Women’s Hospital and Harvard Medical School. They used the measurements of ST-segment depression on ambulatory ECG in patients with CAD. They enrolled 40 patients with proven CAD, total serum cholesterol between 191 and 327 mg/dL, and at least one episode of ST-segment depression on ambulatory ECG monitoring. Patients were randomized to either an AHA Step 2 diet plus placebo, or to the same diet plus treatment with lovastatin. This slide shows the patient-by-patient effect of cholesterol lowering over six months on the number of episodes of ischemic ST-segment depression. Two of 20 in the placebo group vs 13 of 20 in the treatment group show resolution of ischemia.8

Effects of lipid lowering on endothelial function in hypercholesterolemic patients Content Points: The Harvard results were preceded by a study from Anderson et al which explored the extent to which a year of cholesterol-lowering and antioxidant therapy could restore endothelium-dependent coronary vasodilation in patients with elevated cholesterol and LDL-C levels.9 Endothelium-dependent coronary vasomotion response to acetycholine was assessed at baseline and following one year of therapy in three groups of patients: 1) those randomly assigned to the AHA Step 1 diet, 2) lovastatin and cholestyramine, or 3) those assigned to therapy with lovastatin and probucol. Treatment resulted in significant reductions in LDL-C levels in the groups treated pharmacologically to lower LDL-C. Likewise, the two pharmacologically treated groups experienced improvements in coronary artery diameters following acetylcholine administration vs the diet group. Both treatment groups showed improved endothelium-dependent vasomotion with cholesterol lowering; this may help to explain the reduced incidence of adverse coronary events resulting from cholesterol-lowering therapy.

Benefits of aggressive LDL-C lowering Content Points: In summary, the results of studies suggest that the benefits of aggressive LDL-C lowering can result in improvement in endothelial function, decreases in angina and reflex coronary constriction, as well as reduced need for revascularization.